Latest Ratios: P/E Ratio -7.1x · EV/EBITDA N/A · ROE -54.3%. (2019–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $999M | $150M | $145M | $1.7B | $1.0B | — | — |
| Enterprise Value | $982M | $134M | $106M | $1.7B | $930M | — | — |
| P/E Ratio → | -7.11 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 3.77 | 0.59 | 0.59 | 4.86 | 3.59 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -54.3% | -54.3% | -64.6% | -34.3% | -67.4% | — | — |
| ROA | -48.8% | -48.8% | -59.5% | -32.7% | -57.4% | -9486.2% | -1281.7% |
| ROIC | -50.3% | -50.3% | -63.0% | -34.0% | -53.0% | — | — |
| ROCE | -57.2% | -57.2% | -68.1% | -35.7% | -48.3% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.05 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.06 | -0.16 | -0.18 | -0.25 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -678.25 | -19.69 | -28.63 |
Net cash position: cash ($27M) exceeds total debt ($11M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 17.97 | 17.97 | 11.87 | 20.21 | 21.41 | 0.17 | 0.55 |
| Quick Ratio | 17.97 | 17.97 | 11.87 | 20.21 | 21.41 | 0.17 | 0.55 |
| Cash Ratio | 17.01 | 17.01 | 11.33 | 19.44 | 21.05 | 0.17 | 0.49 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $68M | $59M | $52M | $50M | $50M | $2M |
Critical liquidity and funding
Based on current market data, VTYX trades at a price-to-book ratio of 3.77, which, when compared to peers like Arcus Biosciences, suggests that investors are heavily discounting the company's pipeline potential following the recent clinical setbacks in the TYK2 program.
The lack of meaningful P/E or EV/EBITDA multiples underscores the company's pre-revenue status, forcing investors to rely on book value as a floor. This valuation appears to reflect a significant 'clinical failure' discount, implying that the market is currently assigning little to no terminal value to the NLRP3 portfolio.
As reported in financial statements, Ventyx has consistently generated negative ROIC, with figures hovering around -10.5% in 2025Q3, indicating that the firm is currently destroying shareholder capital as it attempts to advance its clinical pipeline without a commercial revenue offset.
The trend of negative returns on invested capital is a direct consequence of high R&D burn rates relative to the lack of product sales. This persistent decay in capital efficiency warrants further investigation into whether the current pipeline pivot can realistically reverse these trends before the cash runway is fully exhausted.
According to recent quarterly filings, the company's current ratio has fluctuated significantly, reaching 17.86 in 2025Q3, yet this metric is misleading as it masks the rapid depletion of cash reserves required to fund ongoing clinical trials and operational overhead.
While the current ratio appears high, it is a function of the company's specific asset composition rather than operational strength. Investors should monitor the absolute cash balance closely, as the current burn rate suggests that the firm's liquidity position is highly vulnerable to even minor delays in clinical milestones.
The price-to-book ratio is frequently misapplied to Ventyx, as it fails to capture the binary nature of clinical-stage biotechnology assets where the true value lies in intangible intellectual property rather than the tangible assets reported on the balance sheet.
Using book value as a proxy for intrinsic value in this context obscures the reality that the company's assets are essentially 'wasting' as they are consumed by R&D. A more appropriate analytical framework would involve a risk-adjusted net present value (rNPV) model that accounts for the probability of success for the NLRP3 program.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VTYX stock.
Ventyx Biosciences, Inc.'s current P/E ratio is -7.1x. This places it at the 50th percentile of its historical range.
Ventyx Biosciences, Inc.'s return on equity (ROE) is -54.3%. The historical average is -55.1%.
Based on historical data, Ventyx Biosciences, Inc. is trading at a P/E of -7.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.